Gutiérrez-Sandoval, R.; Gutiérrez-Castro, F.; Muñoz-Godoy, N.; Rivadeneira, I.; Lagos, A.; Muñoz, I.; Iturra, J.; Krakowiak, F.; Peña-Vargas, C.; Vidal, M.;
et al. Ex Vivo Traceability Platform for Phospholipoproteomic Formulations: Functional Evidence Without Clinical Exposure. Biomedicines 2025, 13, 2101.
https://doi.org/10.3390/biomedicines13092101
AMA Style
Gutiérrez-Sandoval R, Gutiérrez-Castro F, Muñoz-Godoy N, Rivadeneira I, Lagos A, Muñoz I, Iturra J, Krakowiak F, Peña-Vargas C, Vidal M,
et al. Ex Vivo Traceability Platform for Phospholipoproteomic Formulations: Functional Evidence Without Clinical Exposure. Biomedicines. 2025; 13(9):2101.
https://doi.org/10.3390/biomedicines13092101
Chicago/Turabian Style
Gutiérrez-Sandoval, Ramón, Francisco Gutiérrez-Castro, Natalia Muñoz-Godoy, Ider Rivadeneira, Andy Lagos, Ignacio Muñoz, Jordan Iturra, Francisco Krakowiak, Cristián Peña-Vargas, MatÃas Vidal,
and et al. 2025. "Ex Vivo Traceability Platform for Phospholipoproteomic Formulations: Functional Evidence Without Clinical Exposure" Biomedicines 13, no. 9: 2101.
https://doi.org/10.3390/biomedicines13092101
APA Style
Gutiérrez-Sandoval, R., Gutiérrez-Castro, F., Muñoz-Godoy, N., Rivadeneira, I., Lagos, A., Muñoz, I., Iturra, J., Krakowiak, F., Peña-Vargas, C., Vidal, M., & Toledo, A.
(2025). Ex Vivo Traceability Platform for Phospholipoproteomic Formulations: Functional Evidence Without Clinical Exposure. Biomedicines, 13(9), 2101.
https://doi.org/10.3390/biomedicines13092101